A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01351103 |
Recruitment Status :
Active, not recruiting
First Posted : May 10, 2011
Last Update Posted : March 15, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Pancreatic Cancer BRAF Mutant Colorectal Cancer Melanoma Triple Negative Breast Cancer Head and Neck Squamous Cell Cancer Cervical Squamous Cell Cancer Esophageal Squamous Cell Cancer Lung Squamous Cell Cancer | Drug: LGK974 Biological: PDR001 | Phase 1 |
This open-label multicenter phase 1 dose escalation study will be the first to administer LGK974 as a single agent or in combination with PDR001 in humans.
The study will comprise of 2 parts: a dose escalation of LGK974 as a single agent, followed by a safety expansion in specific disease indications; and a dose escalation of LGK974 in combination with PDR001, followed by a safety expansion in cutaneous melanoma.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 185 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase I, Open-label, Dose Escalation Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands |
Actual Study Start Date : | December 1, 2011 |
Actual Primary Completion Date : | June 14, 2021 |
Estimated Study Completion Date : | June 18, 2024 |
Arm | Intervention/treatment |
---|---|
Experimental: LGK974
LGK974
|
Drug: LGK974
Other Name: WNT974 |
Experimental: LGK974 in combination with PDR001
LGK in combination with PDR001
|
Drug: LGK974
Other Name: WNT974 Biological: PDR001 |
- Maximum Tolerated Dose or Recommended Dose for Expansion of LGK974 as a single agent or in combination with PDR001 in patients treated [ Time Frame: 34 months ]Determine the Maximum Tolerated Dose (MTD) or Recommended Dose for Expansion (RDE) of LGK974 as a single agent and in combination with PDR001 when administered orally to adult patients with malignancies dependent on Wnt ligands.
- Type and category of study drug related adverse events (AE) [ Time Frame: 61 months ]The incidence of treatment-emergent adverse events (new or worsening from baseline) will be summarized by primary system organ class, severity based on the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03, type of AE, relationship to study drug by dose group.
- Absorption and plasma concentrations of LGK974 [ Time Frame: 61 months ]Evaluate pharmacokinetic (PK) parameters such as AUClast, AUCtau, Cmax, the apparent elimination T1/2 and Racc for LGK974 and its pharmacologically metabolite.
- PD related to the Wnt pathway [ Time Frame: 61 months ]Assessing percent change from baseline to post-treatment of PD related to the Wnt pathway.
- Overall response rate of tumor [ Time Frame: 61 months ]Patients with an Overall Response Rate(ORR), complete response (CR) or partial response (PR) rate and duration of response (DOR) assessed by RECIST 1.1 for single agent LGK974 and by RECIST1.1 and irRC for LGK974+PDR001.
- Absorportion and plasma concentrations of PDR001 [ Time Frame: 61 months ]Evaluate pharmacokinetic (PK) parameters such as AUClast, AUCtau, Cmax, the apparent elimination T1/2 and Racc for LGK974, its pharmacologically metabolite and PDR001.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Diagnosis of locally advanced or metastatic cancer that has progressed despite standard therapy or for which no effective standard therapy exists and histological confirmation of one of the following diseases indicated below:
Single Agent Dose escalation part:documented B-RAF mutant colorectal cancer or pancreatic adenocarcinoma. In addition, tumors of any histological origin with documented genetic alterations upstream in the Wnt signaling pathway are eligible with prior agreement with Novartis.
Single Agent Dose expansion part: documented B-RAF mutant colorectal cancer with documented RNF43 mutation and/or RSPO fusion or pancreatic adenocarcinoma with documented RNF43 mutation. In addition, patients with tumors of any histological origin with documented genetic alterations upstream in the Wnt signaling pathway (e.g. RNF43 or RSPO fusion) are eligible with prior agreement with Novartis
LGK974 with PDR001: Dose escalation: patients with the following cancers that were previously treated with anti-PD-1 therapy and whose best response on that therapy was progressive disease (i.e. primary refractory): melanoma, lung SCC, HNSCC. Patients with esophageal SCC, cervical SCC or TNBC who are either naïve or primary refractory to prior anti-PD-1 therapy.
LGK974 with PDR001: Dose expansion: patients with:
- cutaneous melanoma that was primary refractory to prior anti-PD-1 therapy, defined as a best response of progressive disease or stable disease for <= 4 months, or disease recurrence with the first 6 months of adjuvant therapy. Patients with BRAF V600-mutant melanoma must have also received and been failed by prior systemic therapy with BRAF V600 inhibitor, with or without a MEK inhibitor.
- Cutaneous melanoma with acquired resistance to prior anti-PD-1 therapy, defined as progressive disease following response (PR or CR) or following stable disease for > 4 months. Patients with BRAF V600-mutant melanoma must have also received and been failed by prior systemic therapy with a BRAF V600 inhibitor, with or without a MEK inhibitor.
Exclusion Criteria:
- Impaired cardiac function
- Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of LGK974 (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection)
- Brain metastases that have not been adequately treated
- Malignant disease other than that being treated in this study
- Laboratory abnormalities as specified in the protocol
- Osteoporosis, osteopenia
- Bone fractures within the past year
- Pathologic bone fracture
- Active, known or suspected autoimmune disease or severe hypersensitivity reactions to other monoclonal antibodies
Other protocol-defined inclusion/exclusion criteria may apply
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01351103
United States, California | |
UCLA School of Medicine | |
Los Angeles, California, United States, 90024 | |
United States, Maryland | |
Sidney Kimmel Comprehensive Cancer Center Johns Hopkins | |
Baltimore, Maryland, United States, 21287-0013 | |
United States, Massachusetts | |
Dana Farber Cancer Institute SC-7 | |
Boston, Massachusetts, United States, 02215 | |
United States, Michigan | |
University of Michigan Comprehensive Cancer Center Onc Dept. | |
Ann Arbor, Michigan, United States, 48109-0944 | |
Karmanos Cancer Institute Wayne St | |
Detroit, Michigan, United States, 48201 | |
United States, Texas | |
University of Texas/MD Anderson Cancer Center MD Anderson 2 | |
Houston, Texas, United States, 77030-4009 | |
Canada, Quebec | |
Novartis Investigative Site | |
Montreal, Quebec, Canada, H2W 1T8 | |
France | |
Novartis Investigative Site | |
Villejuif, France, 94800 | |
Germany | |
Novartis Investigative Site | |
Essen, Germany, 45147 | |
Italy | |
Novartis Investigative Site | |
Milano, MI, Italy, 20133 | |
Novartis Investigative Site | |
Napoli, Italy, 80131 | |
Netherlands | |
Novartis Investigative Site | |
Rotterdam, Netherlands, 3075 EA | |
Novartis Investigative Site | |
Utrecht, Netherlands, 3584CX | |
Spain | |
Novartis Investigative Site | |
Barcelona, Catalunya, Spain, 08035 | |
Novartis Investigative Site | |
Barcelona, Catalunya, Spain, 08036 | |
Novartis Investigative Site | |
Hospitalet de LLobregat, Catalunya, Spain, 08907 | |
Novartis Investigative Site | |
Valencia, Comunidad Valenciana, Spain, 46010 | |
Novartis Investigative Site | |
Madrid, Spain, 28009 | |
Novartis Investigative Site | |
Madrid, Spain, 28040 | |
Novartis Investigative Site | |
Madrid, Spain, 28050 |
Study Director: | Novartis Pharmaceuticals | Novartis Pharmaceuticals |
Responsible Party: | Novartis Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT01351103 |
Other Study ID Numbers: |
CLGK974X2101 2011-000495-33 ( EudraCT Number ) |
First Posted: | May 10, 2011 Key Record Dates |
Last Update Posted: | March 15, 2024 |
Last Verified: | March 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
LGK974 pancreatic adenocarcinoma BRAF mutant colorectal cancer RNF43 mutation RSPO fusion melanoma triple negative breast cancer |
PDR001 immunotherapy head and neck scc cervical scc esophageal scc lung scc |
Colorectal Neoplasms Melanoma Triple Negative Breast Neoplasms Neoplasms, Squamous Cell Carcinoma, Squamous Cell Esophageal Squamous Cell Carcinoma Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Digestive System Diseases |
Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Rectal Diseases Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms, Nerve Tissue Nevi and Melanomas Skin Neoplasms Neoplasms, Glandular and Epithelial Carcinoma Esophageal Neoplasms Head and Neck Neoplasms |